Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy

Cancer immunotherapy has reached a critical point, now that immune checkpoint inhibitors and two CAR-T products have received market approval in treating 16 types of cancers and 1 tissue-agnostic cancer indica...

Source: Journal of Hematology and Oncology - April 3, 2020 Category: Hematology Authors: Chongxian Pan, Hongtao Liu, Elizabeth Robins, Wenru Song, Delong Liu, Zihai Li and Lei Zheng Tags: Review Source Type: research